January 18 - 22, 2006
Disney's Contemporary Resort
Lake Buena Vista, Florida
Claudio Joazeiro, Genomics Institute of the Novartis Foundation, San Diego, CA
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
Tony Hunter, Salk Institute for Biological Studies, La Jolla, CA
Researchers and scientists from nearly 20 different countries participated in the 2006 AACR Special Conference on Ubiquitin and Cancer: From Molecular Targets and Mechanisms to the Clinic. This conference was unique among other meetings in the protein ubiquitylation field for its strong clinical/translational component, including the review of recent successes with proteasome inhibitors in treating cancer in the clinic, as well as the pre-clinical studies validating ubiquitin ligase inhibitors for cancer therapy.
Specifically, the conference objectives were to: 1) provide an overview of the field of protein ubiquitylation, including review and discussion of the UPS-mediated regulation of various cellular processes that are relevant for cancer; 2) foster discussions on the role of the UPS in malignancy and the opportunities for therapeutic intervention (drug targets); 3) evaluate the successes and limitations of existing as well as proposed therapeutic approaches to interfere with the UPS; 4) provide a forum for interaction among cancer scientists and experts in the field of protein ubiquitylation; 5) contribute to the education of young scientists and others interested in the fields of cancer and the UPS. The conference fostered extensive discussion on therapeutic opportunities, therapeutic approaches, and the role of the UPS in malignancy. Emphasis was given to the challenges involved in target identification and validation, and in drug development.
*(Adobe Acrobat Reader required)
Please visit the AACR Meeting Calendar for a complete list of upcoming programs.